soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ Heart and SOUL โ oral
Description
This article describes the causes of gynecomastia, a condition characterized by the development of enlarged breasts in males.
A doctor explains options for patients.
Good during April, May & June of 2026.
Emanuel EJ, Dellgren JL, McCoy MS
GLP-1 drugs subsequently proved their mettle to treat obesity and prevent major cardiovascular events and will likely soon be available to treat sleep apnea as well
Learn risks to teeth and gums and how to protect your smile effectively.
